Low sexual desire is a prevalent symptom, but not one frequently volunteered by women. When accompanied by distress, loss of libido is known as hypoactive sexual desire disorder, which can have a significant impact on a woman's wellbeing. The etiology of hypoactive sexual desire disorder is multifactorial and its management requires a combination of psychosocial and pharmacological interventions. This article outlines the assessment of patients presenting with the symptom of low sexual desire and discusses the evidence for pharmacological management.
ShifrenJLMonzBURussoPASegretiAJohannesCB. Sexual problems and distress in United States women. Prevalence and correlates. Obstet. Gynecol.112(5), 970–978 (2008).
5.
MastersWHJohnsonVE. Human Sexual Response.Little, Brown and company, Boston, MA, USA (1966).
6.
KaplanHS. Hypoactive sexual desire. J. Sex Marital Ther.3(1), 3–9 (1977).
7.
BassonR. Using a different model for female sexual response to address women's problematic low sexual desire. J. Sex Marital Ther.27(5), 395–403 (2001).
8.
American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders.4th edition, text revision (DSM-IV-TR). American Psychiatric Association, Washington DC, USA (2000).
9.
World Health Organization.International Statistical Classification of Diseases and Related Health Problems.10th revision. World Health Organization, Geneva, Switzerland (1992).
10.
BassonRLeiblumSBrottoL. Definitions of women's sexual dysfunctions reconsidered: advocating expansion and revision. J. Psychosom. Obstet. Gynaecol.24(4), 221–229 (2003).
11.
BassonRWiermanMvan LankveldJBrottoLA. Summary of the recommendations of sexual dysfunction in women. J. Sex. Med.7(1 Pt 2), 314–326 (2010).
12.
BrottoLABitzerJLaanELeiblumSLuriaM. Women's sexual desire and arousal disorders. J. Sex. Med.7(1 Pt 2), 586–614 (2010).
13.
BrottoLA. The DSM diagnostic criteria for hypoactive sexual desire disorder in women. Arch. Sex Behav.39(2), 221–239 (2010).
14.
LaumannEOPaikARosenRC. Sexual dysfunction in the United States. prevalence and predictors. JAMA281(6), 537–544 (1999).
15.
MoynihanR. Merging of marketing and medical science. BMJ341, 698–700 (2010).
16.
LeiblumSRKoochakiPERodenbergCABartonIPRosenRC. Hypoactive sexual desire disorder in postmenopausal women. US results from the Women's International Study of Health and Sexuality (WISHeS). Menopause13(1), 46–56 (2006).
17.
US results from this important cross-sectional study to determine the prevalence of hypoactive sexual desire disorder
18.
DennersteinLKoochakiPBartonIGraziottinA. Hypoactive sexual desire disorder in menopausal women: a survey of Western European women. J. Sex. Med.3(2), 212–222 (2006).
19.
European results from the Women's International Study of Health and Sexuality investigating the prevalence of hypoactive sexual desire disorder
20.
HayesRDDennersteinLBennettCMKoochakiPELeiblumSRGraziottinA. Relationship between hypoactive sexual desire disorder and aging. Fertil. Steril.87(1), 107–112 (2007).
21.
WestSLD'AloisioAAAgansRPKalsbeekWDBorisovNNThorpJM. Prevalence of low sexual desire and hypoactive sexual desire disorder in a nationally representative sample of US women. Arch. Intern. Med.168(13), 1441–1449 (2008).
22.
BiddleAKWestSLD'AloisioAAWheelerSBBorisovNNThorpJ. Hypoactive sexual desire disorder in postmenopausal women: quality of life and health burden. Value Health.12(5), 763–772 (2009).
23.
PfausJG. Pathways of sexual desire. J. Sex. Med.6(6), 1506–1533 (2009).
24.
NEW REF 1 Hull EM, LorrainDSDuJ. Hormone-neurotransmitter interactions in the control of sexual behavior. Behav. Brain Res.105(1), 105–116 (1999).
25.
GenazzaniARSchneiderHPPanayNNijlandEA. The European Menopause Survey 2005. Women's perceptions on the menopause and postmenopausal hormone therapy. Gynecol. Endocrinol.22(7), 369–375 (2006).
26.
LevineKBWilliamsREHartmannKE. Vulvovaginal atrophy is strongly associated with female sexual dysfunction among sexually active postmenopausal women. Menopause15(4 Pt 1), 661–666 (2008).
27.
BassonR. Women's sexual function and dysfunction: current uncertainties, future directions. Int. J. Impot. Res.20(5), 466–478 (2008).
28.
ShifrenJL. The role of androgens in female sexual dysfunction. Mayo Clin. Proc.79(Suppl. 4), S19–S24 (2004).
29.
ZumoffBStrainGWMillerLKRosnerW. Twenty-four-hour mean plasma testosterone concentration declines with age in normal premenopausal women. J. Clin. Endocrinol. Metab.80(4), 1429–1430 (1995).
30.
DemersLM. Androgen deficiency in women; role of accurate testosterone measurements. Maturitas67(1), 39–45 (2010).
31.
LabrieFLuu-TheVLabrieC. Endocrine and intracrine sources of androgens in women. inhibition of breast cancer and other roles of androgens and their precursor dehydroepiandrosterone. Endocr. Rev.24(2), 152–182 (2003).
32.
LaughlinGABarrett-ConnorEKritz-SilversteinDvon MühlenD. Hysterectomy, oophorectomy, and endogenous sex hormone levels in older women: the Rancho Bernardo Study. J. Clin. Endocrinol. Metab.85(2), 645–651 (2000).
33.
DavisonSLBellRDonathSMontaltoJGDavisSR. Androgen levels in adult females: changes with age, menopause, and oophorectomy. J. Clin. Endocrinol. Metab.90(7), 3847–3853 (2005).
34.
van der StegeJGGroenHvan ZadelhoffSJ. Decreased androgen concentrations and diminished general and sexual well-being in women with premature ovarian failure. Menopause15(1), 23–31 (2008).
35.
KalantaridouSNCalisKAVanderhoofVH. Testosterone deficiency in young women with 46,XX spontaneous premature ovarian failure. Fertil. Steril.86(5), 1475–1482 (2006).
36.
KalantaridouSNVanderhoofVHCalisKACorriganECTroendleJFNelsonLM. Sexual function in young women with spontaneous 46,XX primary ovarian insufficiency. Fertil. Steril.90(5), 1805–1811 (2008).
37.
de AlmeidaDMBenetti-PintoCLMakuchMY. Sexual function of women with premature ovarian failure. Menopause18(3), 262–266 (2011).
38.
DennersteinLHayesRSandMLehertP. Attitudes toward and frequency of partner interactions among women reporting decreased sexual desire. J. Sex. Med.6(6), 1668–1673 (2009).
39.
HarshVMcGarveyELClaytonAH. Physician attitudes regarding hypoactive sexual desire disorder in a primary care clinic: a pilot study. J. Sex. Med.5(3), 640–645 (2008).
40.
ClaytonAHGoldfischerERGoldsteinIDerogatisLLewis-DAgostinoDJPykeR. Validation of the decreased sexual desire screener (DSDS): a brief diagnostic instrument for generalized acquired female hypoactive sexual desire disorder (HSDD). J. Sex. Med.6(3), 730–738 (2009).
41.
RosenRBrownCHeimanJ. The Female Sexual Function Index (FSFI): a multidimensional self-report instrument for the assessment of female sexual function. J. Sex Marital Ther.26(2), 191–208 (2000).
42.
McHorneyCARustJGolombokS. Profile of female sexual function: a patient-based, international, psychometric instrument for the assessment of hypoactive sexual desire in oophorectomized women. Menopause11(4), 474–483 (2004).
43.
Al-AzzawiFBitzerJBrandenburgU. Therapeutic options for postmenopausal female sexual dysfunction. Climacteric.13(2), 103–120 (2010).
44.
McCabeMAlthofSEAssalianP. Psychological and interpersonal dimensions of sexual function and dysfunction. J. Sex. Med.7(1 Pt 2), 327–336 (2010).
45.
McCabeMP. Evaluation of a cognitive behavior therapy program for people with sexual dysfunction. J. Sex Marital Ther.27(3), 259–271 (2001).
46.
TrudelGMarchandARavartMAubinSTurgeonLFortierP. The effect of a cognitive-behavioral treatment program on hypoactive sexual desire in women. Sex. Relat. Ther.16(2), 145–164 (2001).
47.
PalaciosS. Hypoactive sexual desire disorder and current pharmacotherapeutic options in women. Women's Health (Lond. Engl.).7(1), 95–107 (2011).
48.
NappiREPolattiF. The use of estrogen therapy in women's sexual functioning (CME). J. Sex. Med.6(3), 603–616 (2009).
49.
A clinically useful review on the importance of estrogen therapy to improve postmenopausal sexual functioning
50.
SucklingJLethabyAKennedyR. Local oestrogen for vaginal atrophy in postmenopausal women. Cochrane Database Syst. Rev. (4), CD001500 (2005).
51.
SturdeeDWPanayN; International Menopause Society Writing Group. Recommendations for the management of postmenopausal vaginal atrophy. Climacteric13(6), 509–522 (2010).
52.
Comprehensive guidelines exploring the physiology of vulvovaginal atrophy and its impact on postmenopausal health, along with recommendations for management
53.
FlöterANathorst-BöösJCarlströmKvon SchoultzB. Addition of testosterone to estrogen replacement therapy in oophorectomized women: effects on sexuality and well-being. Climacteric5(4), 357–365 (2002).
54.
LoboRARosenRCYangHMBlockBVan Der HoopRG. Comparative effects of oral esterified estrogens with and without methyltestosterone on endocrine profiles and dimensions of sexual function in postmenopausal women with hypoactive sexual desire. Fertil. Steril.79(6), 1341–1352 (2003).
55.
ShifrenJLBraunsteinGDSimonJA. Transdermal testosterone treatment in women with impaired sexual function after oophorectomy. N. Engl. J. Med.343(10), 682–688 (2000).
56.
BraunsteinGDSundwallDAKatzM. Safety and efficacy of a testosterone patch for the treatment of hypoactive sexual desire disorder in surgically menopausal women: a randomized, placebo-controlled trial. Arch. Intern. Med.165(14), 1582–1589 (2005).
57.
BusterJEKingsbergSAAguirreO. Testosterone patch for low sexual desire in surgically menopausal women: a randomized trial. Obstet. Gynecol.105(5 Pt 1), 944–952 (2005).
58.
SimonJBraunsteinGNachtigallL. Testosterone patch increases sexual activity and desire in surgically menopausal women with hypoactive sexual desire disorder. J. Clin. Endocrinol. Metab.90(9), 5226–5233 (2005).
59.
ShifrenJLDavisSRMoreauM. Testosterone patch for the treatment of hypoactive sexual desire disorder in naturally menopausal women: results from the INTIMATE NM1 Study. Menopause13(5), 770–779 (2006).
60.
PanayNAl-AzzawiFBouchardC. Testosterone treatment of HSDD in naturally menopausal women: the ADORE study. Climacteric13(2), 121–131 (2010).
61.
A randomized, double-blind, placebo-controlled study of the transdermal testosterone patch in 272 naturally menopausal women
62.
DavisSRMoreauMKrollR. Testosterone for low libido in postmenopausal women not taking estrogen. N. Engl. J. Med.359(19), 2005–2017 (2008).
63.
An important randomized controlled trial investigating the use of the transdermal testosterone patch in postmenopausal women not on concomitant estrogen
64.
NachtigallLCassonPLucasJSchofieldVMelsonCSimonJA. Safety and tolerability of testosterone patch therapy for up to 4 years in surgically menopausal women receiving oral or transdermal oestrogen. Gynecol. Endocrinol.27(1), 39–48 (2011).
65.
StuddJWWCollinsWPChakravartiSNewtonJROramDParsonsA. Oestradiol and testosterone implants in the treatment of psychosexual problems of postmenopausal women. Br. J. Obstet. Gynecol.84(4), 314–315 (1977).
66.
BurgerHHailesJNelsonJMenelausM. Effect of combined implants of oestradiol and testosterone on libido in postmenopausal women. Br. Med. J. (Clin. Res. Ed.)294(6577), 936–937 (1987).
67.
DavisSRMcCloudPStraussBJBurgerH. Testosterone enhances estradiol's effects on postmenopausal bone density and sexuality. Maturitas21(3), 227–236 (1995).
68.
GlaserRYorkAEDimitrakakisC. Beneficial effects of testosterone therapy in women measured by the validated Menopause Rating Scale (MRS). Maturitas68(4), 355–361 (2011).
69.
Nathorst-BöösJFlöterAJarkander-RolffMCarlströmKSchoultzB. Treatment with percutanous testosterone gel in postmenopausal women with decreased libido - effects on sexuality and psychological general well-being. Maturitas53(1), 11–18 (2006).
70.
ChudakovBBen ZionIZBelmakerRH. Transdermal testosterone gel prn application for hypoactive sexual desire disorder in premenopausal women: a controlled pilot study of the effects on the arizona sexual experiences scale for females and sexual function questionnaire. J. Sex. Med.4(1), 204–208 (2007).
71.
Castelo-BrancoCVicenteJJFiguerasF. Comparative effects of estrogens plus androgens and tibolone on bone, lipid pattern and sexuality in postmenopausal women. Maturitas34(2), 161–168 (2000).
72.
LaanEvan LunsenRHEveraerdW. The effects of tibolone on vaginal blood flow, sexual desire and arousability in postmenopausal women. Climacteric4(1), 28–41 (2001).
73.
NijlandEAWeijmar SchultzWCNathorst-BoösJ. Tibolone and transdermal E2/NETA for the treatment of female sexual dysfunction in naturally menopausal women: results of a randomized active-controlled trial. J. Sex. Med.5(3), 646–656 (2008).
74.
CummingsSREttingerBDelmasPD. The effects of tibolone in older postmenopausal women. N. Engl. J. Med.359(7), 697–708 (2008).
75.
LabrieFBélangerACusanLGomezJLCandasB. Marked decline in serum concentrations of adrenal C19 sex steroid precursors and conjugated androgen metabolites during aging. J. Clin. Endocrinol. Metab.82(8), 2396–2402 (1997).
76.
PanjariMDavisSR. DHEA for postmenopausal women: a review of the evidence. Maturitas66(2), 172–179 (2010).
77.
LabrieFArcherDBouchardC. Effect of intravaginal dehydroepiandrosterone (Prasterone) on libido and sexual dysfunction in postmenopausal women. Menopause16(5), 923–931 (2009).
78.
StahlSMSommerBAllersKA. Multifunctional pharmacology of flibanserin: possible mechanism of therapeutic action in hypoactive sexual desire disorder. J. Sex. Med.8(1), 15–27 (2011).
79.
JollyEClaytonAHThorpJ. Efficacy of flibanserin 100 mg qhs as a potential treatment for hypoactive sexual desire disorder in premenopausal women. J. Sex. Med.6(Suppl. 5), 465 (2009).
80.
SegravesRTClaytonACroftHWolfAWarnockJ. Bupropion sustained release for the treatment of hypoactive sexual desire disorder in premenopausal women. J. Clin. Psychopharmacol.24(3), 339–342 (2004).
81.
SafarinejadMRHosseiniSYAsgariMADadkhahFTaghvaA. A randomized, double-blind, placebo-controlled study of the efficacy and safety of bupropion for treating hypoactive sexual desire disorder in ovulating women. BJU Int.106(6), 832–839 (2010).
82.
DordingCMMischoulonDPetersenTJ. The pharmacologic management of SSRI-induced side effects: a survey of psychiatrists. Ann. Clin. Psychiatry14(3), 143–147 (2002).
83.
SafarinejadMR. Reversal of SSRI-induced female sexual dysfunction by adjunctive bupropion in menstruating women: a double-blind, placebo-controlled and randomized study. J. Psychopharmacol.25(3), 370–378 (2011).
84.
MollJLBrownCS. The use of monoamine pharmacological agents in the treatment of sexual dysfunction: evidence in the literature. J. Sex. Med.8(4), 956–970 (2011).
